US warns of cancer-agent in Japan weight loss pills

The US Food and Drug Administration on Tuesday warned consumers not to take a product called "Japan Rapid Weight Loss Diet Pills" because they contain a suspected cancer-causing agent.

The pills, advertised as promoting weight loss, are distributed by a company called Xiushentang and sold on popular web sites including Amazon.com, said the FDA.

Consumers are advised to stop using the pills -- which are packaged in three colors: green, yellow and blue -- and discard them. They should also see a doctor if they have experienced any side effects, the agency said.

An FDA lab analysis has confirmed that the pills, "Japan Rapid Weight Loss Diet Pills Green" contain "undeclared phenolphthalein," the agency said in a statement.

"Phenolphthalein is a solution used in chemical experiments and a suspected cancer-causing agent that is not approved for marketing in the United States."

The FDA has classified the agent as "not generally recognized as safe and effective," and it has been found to potentially damage or even cause mutations in a person's DNA, the warning said.

A similar notice was issued for "Japan Rapid Weight Loss Diet Pills Yellow" because they contain both phenolphthalein and sibutramine, a weight loss agent found in the drug Meridia that was removed from the market in 2010 because it boosted the risk of heart attack and stroke.

"The product poses a threat to consumers because sibutramine is known to substantially increase blood pressure and/or in some patients and may present a significant risk for patients with a history of , , arrhythmias or stroke," the FDA said.

A third product, "Japan Weight Loss Blue" contains sibutramine and ephedrine alkaloids. Products containing ephedra have been banned because they can boost blood pressure to risky levels.

The agency said the dangerous weight loss pills are part of an emerging trend in which companies sell products purporting to be dietary supplements but which contain hidden ingredients that can be harmful.

add to favorites email to friend print save as pdf

Related Stories

FDA declines to approve Orexigen diet drug

Feb 01, 2011

(AP) -- Orexigen Therapeutics Inc. shares plunged nearly 75 percent in pre-market trading Tuesday after U.S. health officials declined to approve the experimental weight loss pill Contrave.

Experimental diet pill shows promise, little risk

Jul 14, 2010

(AP) -- An experimental diet pill helped about half the people who tried it lose some weight and keep it off a year later, without the heart problems that some earlier drugs caused, a study found.

FTC sues Arizona company over acai pill free trials

Aug 16, 2010

(AP) -- The Federal Trade Commission says an Arizona company defrauded consumers who signed up for free trials of acai (ah-sah-EE') berry weight-loss pills and colon cleansing supplements.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

13 minutes ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments